153241-03-3

Upstream product

• 121124-94-5 2-benzyloxy-5-bromobenzaldehyde 
• 1761-61-1 5-bromosalicyclaldehyde 
• 100-39-0 benzyl bromide 

Downstream Products

• 202735-21-5 1-(benzyloxy)-4-bromo-2-(tert-butyldimethylsilyloxy)benzene 
• 1038436-37-1 (R)-(-)-1-[2-(benzyloxy)-5-bromophenoxy]-3,3-dimethylbutan-2-ol 
• 202721-88-8 4-(benzyloxy)-3',6'-dimethoxy-[1,1':4',1'']terphenyl-3,2',4''-triol 
• 202735-36-2 4'-benzyloxy-4-bromo-3,6-dimethoxy-biphenyl-2,3'-diol 
• 202721-45-7 methanesulfonic acid 4''-(benzyloxy)-4,3'-bis(methanesulfonyloxy)-2',5'-dimethoxy-[1,1':4',1'']terphenyl-3''-yl ester 
• 213459-69-9 4-benzyloxy-4''-(methanesulfonyloxy)-3',6'-dimethoxy-[1,1':4',1'']terphenyl-3,2'-diol 
• 202735-22-6 4-(benzyloxy)-3-(tert-butyldimethylsilyloxy)benzeneboronic acid 

Relevant academic research and scientific papers

Development of DHQ-based chemical biology probe to profile cellular targets for HBV

Chronic hepatitis B virus (HBV) infection has been a serious public health burden worldwide. Current anti-HBV therapies could not eliminate HBV ultimately. Considering the characteristics of HBV, it is impossible to be entirely cured based on current therapies. Therefore, it is urgently needed to develop novel therapeutic agents with new mechanism of action. The dihydroquinolizinone (DHQ) derivatives exhibited potent anti-HBV activity by decreasing HBV DNA and HBsAg level in an obscure mechanism of action. In this study, we have optimized the DHQ scaffold, developed the photoaffinity probe, with which to identify potential binding proteins.

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The invention also relates to the use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

Highly diastereoselective synthesis of orthoquinone monoketals through λ13-iodane-mediated oxidative dearomatization of phenols

(Chemical Equation Presented) Versatile chiral substrates for asymmetric synthesis are formed through the spiroketalization of phenols with a chiral substituted ethanol unit O-tethered to the ortho position upon treatment with PhI-(OAc)2 (see example; TFE = 2,2,2-tri-fluoroethanol). Intermediates with a six-membered iodine(III)-containing ring (the natural localized molecular orbitals associated with the I-C6 bond are shown) undergo ligand coupling to give the spiroketals.